欧盟EMA药品数据库(European Medicines Agency Authorisation of Medicines DataBase)
商品名称Prevenar 13
适用类别Human
治疗领域Pneumococcal Infections;Immunization
通用名/非专利名称pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)
活性成分Pneumococcal polysaccharide serotype 1;Pneumococcal polysaccharide serotype 3;Pneumococcal polysaccharide serotype 4;Pneumococcal polysaccharide serotype 5;Pneumococcal polysaccharide serotype 6A;Pneumococcal polysaccharide serotype 6B;Pneumococcal polysaccharide serotype 7F;Pneumococcal polysaccharide serotype 9V;Pneumococcal polysaccharide serotype 14;Pneumococcal polysaccharide serotype 18C;Pneumococcal polysaccharide serotype 19A;Pneumococcal polysaccharide serotype 19F;Pneumococcal polysaccharide serotype 23F
产品号EMEA/H/C/001104
患者安全信息No
许可状态Authorised
ATC编码J07AL02
是否额外监管No
是否仿制药或hybrid药物No
是否生物类似药No
是否附条件批准No
是否特殊情形No
是否加速审评No
是否罕用药No
上市许可日期2009/12/09
上市许可开发者/申请人/持有人Pfizer Europe MA EEIG
人用药物治疗学分组Vaccines
兽用药物治疗学分组
审评意见日期2009/09/24
欧盟委员会决定日期2025/04/24
修订号49
治疗适应症Active immunisation for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae in infants, children and adolescents from 6 weeks to 17 years of age. Active immunisation for the prevention of invasive disease caused by Streptococcus pneumoniae in adults ?18 years of age and the elderly. See sections 4.4 and 5.1 for information on protection against specific pneumococcal serotypes. The use of Prevenar 13 should be determined on the basis of official recommendations taking into consideration the risk of invasive disease in different age groups, underlying comorbidities as well as the variability of serotype epidemiology in different geographical areas.
适用物种
兽用药物ATC编码
首次发布日期2018/03/19
最后更新日期2025/04/24
产品说明书https://www.ema.europa.eu/en/documents/product-information/prevenar-13-epar-product-information_en.pdf
公共评估报告https://www.ema.europa.eu/en/medicines/human/EPAR/prevenar-13
©2006-2025 DrugFuture->European Medicines Agency Authorisation of Medicines DataBase